Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benedikt Winter

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Bulletin of the World Health Organization|September 18, 2004
Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected populationJörg Heukelbach, Benedikt Winter, Thomas Wilcke, et al.
Metabolic Engineering|December 24, 2021
The metabolic potential of plastics as biotechnological carbon sources - Review and targets for the futureTill Tiso, Benedikt Winter, Ren Wei, et al.
Therapeutic Advances in Neurological Disorders|June 18, 2019
Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatmentClaudia D Wurster, René Günther, Petra Steinacker, et al.
Annals of Clinical and Translational Neurology|August 11, 2022
Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophyMaren Freigang, Petra Steinacker, Claudia D Wurster, et al.
Journal of Neurology|September 26, 2019
Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersenClaudia D Wurster, Petra Steinacker, René Günther, et al.
Frontiers in Neurology|December 3, 2019
Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With NusinersenClaudia D Wurster, Jan C Koch, Isabell Cordts, et al.
Journal of Neuromuscular Diseases|November 21, 2019
Treatment with Nusinersen - Challenges Regarding the Indication for Children with SMA Type 1Astrid Pechmann, Matthias Baumann, Günther Bernert, et al.
The Lancet. Child & Adolescent Health|November 10, 2021
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort studyClaudia Weiß, Andreas Ziegler, Lena-Luise Becker, et al.
Journal of Neuromuscular Diseases|December 4, 2022
Newbornscreening SMA - From Pilot Project to Nationwide Screening in GermanyWolfgang Müller-Felber, Astrid Blaschek, Oliver Schwartz, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Bulletin of the World Health Organization|September 18, 2004
Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected populationJörg Heukelbach, Benedikt Winter, Thomas Wilcke, et al.
Metabolic Engineering|December 24, 2021
The metabolic potential of plastics as biotechnological carbon sources - Review and targets for the futureTill Tiso, Benedikt Winter, Ren Wei, et al.
Therapeutic Advances in Neurological Disorders|June 18, 2019
Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatmentClaudia D Wurster, René Günther, Petra Steinacker, et al.
Annals of Clinical and Translational Neurology|August 11, 2022
Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophyMaren Freigang, Petra Steinacker, Claudia D Wurster, et al.
Journal of Neurology|September 26, 2019
Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersenClaudia D Wurster, Petra Steinacker, René Günther, et al.
Frontiers in Neurology|December 3, 2019
Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With NusinersenClaudia D Wurster, Jan C Koch, Isabell Cordts, et al.
Journal of Neuromuscular Diseases|November 21, 2019
Treatment with Nusinersen - Challenges Regarding the Indication for Children with SMA Type 1Astrid Pechmann, Matthias Baumann, Günther Bernert, et al.
The Lancet. Child & Adolescent Health|November 10, 2021
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort studyClaudia Weiß, Andreas Ziegler, Lena-Luise Becker, et al.
Journal of Neuromuscular Diseases|December 4, 2022
Newbornscreening SMA - From Pilot Project to Nationwide Screening in GermanyWolfgang Müller-Felber, Astrid Blaschek, Oliver Schwartz, et al.
Pageof 3